7+3	Cytarabine plus anthracycline induction chemotherapy
α-KG	Alpha-ketoglutarate
ADMIRAL	Phase III trial of gilteritinib in relapsed/refractory AML
AGILE	Phase III trial of ivosidenib plus azacitidine
ALL	Acute lymphoblastic leukemia
ALT	Alanine aminotransferase
AML	Acute myeloid leukemia
APL	Acute promyelocytic leukemia
ATRA	All-trans retinoic acid
ATO	Arsenic trioxide
Aza	Azacitidine
BID	Twice daily
CI	Confidence interval
CR	Complete remission
CRc	Composite complete remission
CRh	Complete remission with partial hematologic recovery
CRi	Complete remission with incomplete hematologic recovery
CTCAE	Common Terminology Criteria for Adverse Events
Dec/Ced	Decitabine/cedazuridine
DLT	Dose-limiting toxicity
DS	Differentiation syndrome
EFS	Event-free survival
FDA	U.S. Food and Drug Administration
FLT3	FMS-like tyrosine kinase 3
HOX	Homeobox gene family
HR	Hazard ratio
IDH1/2	Isocitrate dehydrogenase 1/2
IPSS	International Prognostic Scoring System
ITD	Internal tandem duplication
KMT2A	Lysine methyltransferase 2A
KMT2Ar	KMT2A-rearranged
MEIS1	Myeloid ecotropic viral integration site 1
MEN1	Menin gene
MDS	Myelodysplastic syndrome
MPN	Myeloproliferative neoplasm
MRD	Measurable residual disease
ND	Newly diagnosed
NGS	Next-generation sequencing
NPM1	Nucleophosmin 1
NPM1m	NPM1-mutated
ODAC	Oncologic Drugs Advisory Committee
ORR	Overall response rate
OS	Overall survival
PML–RARA	Promyelocytic leukemia–retinoic acid receptor alpha fusion
QTc	Corrected QT interval
R/R	Relapsed or refractory
RP2D	Recommended phase II dose
SANRA	Scale for the Assessment of Narrative Review Articles
STAT5A	Signal transducer and activator of transcription 5A
TEAE	Treatment-emergent adverse event
TKD	Tyrosine kinase domain
TRAEs	Treatment-related adverse events
Ven	Venetoclax